Metropolitan Life Insurance Co. NY lifted its holdings in CytomX Therapeutics Inc (NASDAQ:CTMX) by 376.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,479 shares of the biotechnology company’s stock after purchasing an additional 10,650 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in CytomX Therapeutics were worth $204,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of CytomX Therapeutics by 19.9% in the third quarter. BlackRock Inc. now owns 3,868,566 shares of the biotechnology company’s stock worth $71,570,000 after purchasing an additional 642,165 shares in the last quarter. Perceptive Advisors LLC boosted its stake in CytomX Therapeutics by 9.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,911,715 shares of the biotechnology company’s stock valued at $43,588,000 after buying an additional 250,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in CytomX Therapeutics by 18.3% during the third quarter. Vanguard Group Inc. now owns 2,504,987 shares of the biotechnology company’s stock valued at $46,343,000 after buying an additional 387,722 shares in the last quarter. Vanguard Group Inc boosted its stake in CytomX Therapeutics by 18.3% during the third quarter. Vanguard Group Inc now owns 2,504,987 shares of the biotechnology company’s stock valued at $46,343,000 after buying an additional 387,722 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in CytomX Therapeutics by 7.7% during the third quarter. Renaissance Technologies LLC now owns 1,520,500 shares of the biotechnology company’s stock valued at $28,129,000 after buying an additional 109,000 shares in the last quarter. 83.82% of the stock is owned by institutional investors.
In related news, General Counsel Lloyd A. Rowland bought 9,000 shares of CytomX Therapeutics stock in a transaction dated Monday, March 4th. The stock was acquired at an average cost of $10.33 per share, with a total value of $92,970.00. Following the completion of the acquisition, the general counsel now directly owns 9,979 shares in the company, valued at approximately $103,083.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 8.50% of the company’s stock.
Shares of CTMX stock opened at $10.53 on Tuesday. CytomX Therapeutics Inc has a fifty-two week low of $9.38 and a fifty-two week high of $29.37. The stock has a market cap of $484.95 million, a P/E ratio of -5.19 and a beta of 0.68.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.23). CytomX Therapeutics had a negative net margin of 142.19% and a negative return on equity of 89.22%. The company had revenue of $11.47 million for the quarter, compared to analysts’ expectations of $13.48 million. On average, equities analysts forecast that CytomX Therapeutics Inc will post -2.18 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “CytomX Therapeutics Inc (CTMX) Stake Lifted by Metropolitan Life Insurance Co. NY” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/4296202/cytomx-therapeutics-inc-ctmx-stake-lifted-by-metropolitan-life-insurance-co-ny.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Article: What is a Market Correction?
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.